FDA Approves Omeros’ YARTEMLEA® – First and Only Therapy Indicated for TA-TMA
SEATTLE--(BUSINESS WIRE)--Dec 24, 2025-- Omeros Corporation (NASDAQ: OMER) today announced that the U.S. Food and Drug Administration (FDA) has approved YARTEMLEA ® (narsoplimab-wuug) for the treatment of hematopoietic stem cell transplant-associated …